News | Heart Failure | November 21, 2019

Positive Results for SIRONA First-in-Human Trial of the Cordella PA Pressure Sensor System

Data presented at AHA 2019 showed positive impact on heart failure patients

The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella Pulmonary Artery (PA) Pressure Sensor System. Data was presented at the 2019 American Heart Association (AHA) scientific sessions by Prof. Dr. Wilfried Mullens of the Hospital Oost-Limburg in Genk, Belgium.

"Chronic heart failure patients too frequently have cycles of decompensation and hospitalization that negatively impact patient outcomes and drive up treatment costs. Recent data shows that using PA pressure-guided therapy with this population keeps them healthier and out of the hospital," Mullens explained. "The Cordella System is an elegant solution that integrates a PA pressure sensor and a comprehensive patient management platform in one. The straightforward sensor implant provides reliable pressure data, while the patient management platform enables a comprehensive clinical picture of the patient that allows my team to make informed therapy decisions and improve outcomes."

The 90-day results from the first-in-human trial confirm the device safety and accuracy of pressure measurements in the right pulmonary artery using the implanted Cordella Sensor and handheld patient reader. The study included 15 patients across two European sites: Mullens in Belgium and Dr. Faisal Sharif of the National University of Ireland (NUI) in Galway, Ireland.

 

SIRONA Trial Highlights

The primary accuracy endpoint was met with no significant difference in measured mean PA pressure for the Cordella Sensor and the reference catheter at 90 days.

The study demonstrated encouraging safety results with zero device related system complications (DSRC) at 90 days.

High patient compliance (>98%) with daily remote measurements of vital signs and PA pressure throughout the study.

"The presentation of our first-in-human data at AHA this year is another exciting milestone for the company," said Dr. Katrin Leadley, Chief Medical Officer of Endotronix. "This work lays the clinical foundation for our groundbreaking IDE trial, PROACTIVE-HF, which will begin enrollment in the U.S. later this year. Designed to provide the highest level of clinical evidence for PA pressure-guided therapy, PROACTIVE-HF will support U.S. market access of the Cordella Sensor and inform a national coverage decision from the Centers for Medicare & Medicaid Services (CMS)."

The Cordella Sensor is not available for commercial use in any geography and is under clinical investigation in Europe (SIRONA II CE Mark Trial) and the U.S. (PROACTIVE-HF IDE Trial). 

 

The Cordella Heart Failure System

The Cordella system is designed to help patients suffering from chronic heart failure feel better and stay out of the hospital with streamlined care and remote medication titration. The system provides a comprehensive health status of the patient at home with easy-to-use tools to securely collect and share health related data with healthcare providers for trend-based management. The Cordella Sensor seamlessly integrates pulmonary artery (PA) pressure data into the Cordella System. Together, they proactively deliver the information necessary to improve patient care between office visits and support reimbursement for care delivery activities.

For more information: www.endotronix.com

 

Find links to all the AHA late-breaking trials and other key news.


Related Content

News | AHA

May 31, 2023 — The American Heart Association (AHA) has announced that teams of research scientists from three ...

Home May 31, 2023
Home
News | AHA

April 18, 2023 — Researchers who studied the impact of adherence to key health metrics on longevity have published ...

Home April 18, 2023
Home
News | AHA

November 15, 2022 — Telehealth is a proven and valuable option for people with cardiovascular disease, however, there ...

Home November 15, 2022
Home
News | AHA

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

Home November 14, 2022
Home
News | AHA

November 10, 2022 ­– Significant findings from the clinical trial, known as “BEST-CLI — Best Endovascular versus Best ...

Home November 10, 2022
Home
Feature | AHA

November 9, 2022 — Seven awardees were honored during the American Heart Association Scientific Sessions (AHA 2022). The ...

Home November 09, 2022
Home
News | AHA

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be ...

Home November 08, 2022
Home
News | AHA

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

Home November 08, 2022
Home
News | AHA

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

Home November 08, 2022
Home
News | AHA

November 8, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

Home November 08, 2022
Home
Subscribe Now